MetaADEDB 2.0 @ LMMD
Atracurium
(XXZSQOVSEBAPGS-UHFFFAOYSA-L)
Structure
SMILES
[O-]S(=O)(=O)c1ccccc1.[O-]S(=O)(=O)c1ccccc1.COc1cc2c(cc1OC)CC[N+](C2Cc1ccc(c(c1)OC)OC)(C)CCC(=O)OCCCCCOC(=O)CC[N+]1(C)CCc2c(C1Cc1ccc(c(c1)OC)OC)cc(c(c2)OC)OC
Type(s)
Approved
Molecular Formula:
C65H82N2O18S2
Molecular Weight:
1243.480
Log P:
11.3261
Hydrogen Bond Acceptor:
18
Hydrogen Bond Donor:
0
TPSA:
257.6
CAS Number(s):
64228-81-5; 96946-42-8
Synonym(s)
1.
Atracurium
2.
Atracurium Besylate
3.
Atracurium Dibesylate
4.
33 A 74
5.
Atracurium Besilate
6.
BW-33A
7.
Relatrac
8.
Tracrium
9.
A 74, 33
10.
BW 33A
11.
BW33A
12.
Besilate, Atracurium
External Link(s)
MeSHD001279
PubChem Compound47320
BindingDB50149881
ChEBI2915
CHEMBLCHEMBL1200527
DrugBankDB00732
KEGGdr:D00758
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Wrong drug administeredFAERS: 15US FAERS
2BradycardiaFAERS: 11US FAERS
3Respiratory FailureFAERS: 9US FAERS
4HypotensionFAERS: 8US FAERS
5Medication ErrorFAERS: 8US FAERS
6Drug ineffectiveFAERS: 7
Canada Vigilance: 1		Canada Vigilance
US FAERS
7Neonatal disorderFAERS: 7US FAERS
8Blood creatine phosphokinase increasedFAERS: 6US FAERS
9Neonatal respiratory failureFAERS: 6US FAERS
10Respiratory arrestFAERS: 6US FAERS
11CyanosisFAERS: 5US FAERS
12Drug effect delayedFAERS: 5US FAERS
13Drug effect incompleteFAERS: 5US FAERS
14Infantile apnoeic attackFAERS: 5US FAERS
15Metabolic acidosisFAERS: 5US FAERS
16Neonatal respiratory arrestFAERS: 5US FAERS
17Accidental exposureFAERS: 4US FAERS
18Cardiac ArrestFAERS: 4US FAERS
19Incorrect route of drug administrationFAERS: 4US FAERS
20Neonatal respiratory acidosisFAERS: 4US FAERS
21OverdoseFAERS: 4US FAERS
22Recurrence of neuromuscular blockadeFAERS: 4US FAERS
23Blood pressure immeasurableFAERS: 3US FAERS
24Drug administration errorFAERS: 3US FAERS
25TachycardiaFAERS: 3US FAERS
26Accidental overdoseFAERS: 2US FAERS
27Anaphylactic shockFAERS: 2US FAERS
28BronchospasmFAERS: 2US FAERS
29Developmental Coordination DisorderFAERS: 2US FAERS
30DiplopiaFAERS: 2US FAERS
31Late metabolic acidosis of newbornFAERS: 2US FAERS
32Pharmaceutical product complaintFAERS: 2US FAERS
33Product administration errorFAERS: 2US FAERS
34Administration site urticariaFAERS: 1US FAERS
35Altered state of consciousnessFAERS: 1US FAERS
36AnxietyFAERS: 1US FAERS
37AstheniaFAERS: 1US FAERS
38BronchiolitisFAERS: 1US FAERS
39BronchopneumoniaFAERS: 1US FAERS
40DemyelinationFAERS: 1US FAERS
41Drug administered at inappropriate siteFAERS: 1US FAERS
42DysarthriaFAERS: 1US FAERS
43Electroencephalogram abnormalFAERS: 1US FAERS
44ErythemaFAERS: 1US FAERS
45FlushingFAERS: 1US FAERS
46HeadacheFAERS: 1US FAERS
47HyperacusisFAERS: 1US FAERS
48Incorrect product storageFAERS: 1US FAERS
49Intentional misuseFAERS: 1US FAERS
50Multi-organ disorderFAERS: 1US FAERS
51Neonatal hypotensionFAERS: 1US FAERS
52Neonatal multi-organ failureFAERS: 1US FAERS
53Neuromuscular blocking therapyFAERS: 1US FAERS
54PhotophobiaFAERS: 1US FAERS
55PneumoniaFAERS: 1US FAERS
56Procedural complicationFAERS: 1US FAERS
57Product label confusionFAERS: 1US FAERS
58Psychomotor skills impairedFAERS: 1US FAERS
59Skin test positiveFAERS: 1US FAERS
60SomnolenceFAERS: 1US FAERS
61Therapeutic product ineffectiveFAERS: 1US FAERS
62Ventricular FibrillationFAERS: 1US FAERS
63WheezingFAERS: 1US FAERS
64Wrong technique in drug usage processFAERS: 1US FAERS
65nervous system disorderFAERS: 1US FAERS
66AsthmaCanada Vigilance: 1Canada Vigilance
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120295

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.